BRCA1 and neoplasm: The most recent NCCN guidelines recommend somatic testing in the up-front setting for BRCA1/2 mutations, NTRK fusions, homologous recombination deficiency (HRD) and tumor biomarkers including microsatellite instability (MSI), mismatch repair deficiency (MMR) and tumor mutation burden (TMB) for all patients [9].